Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus Ankara (MVA) expressing native, full-length S protein (MVA-SARS-2-S) is currently under investigation as a candidate v...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer zu Natrup, Christian, Tscherne, Alina, Dahlke, Christine, Ciurkiewicz, Malgorzata, Shin, Dai-Lun, Fathi, Anahita, Rohde, Cornelius, Kalodimou, Georgia, Halwe, Sandro, Limpinsel, Leonard, Schwarz, Jan H., Klug, Martha, Esen, Meral, Schneiderhan-Marra, Nicole, Dulovic, Alex, Kupke, Alexandra, Brosinski, Katrin, Clever, Sabrina, Schünemann, Lisa-Marie, Beythien, Georg, Armando, Federico, Mayer, Leonie, Weskamm, Marie L., Jany, Sylvia, Freudenstein, Astrid, Tuchel, Tamara, Baumgärtner, Wolfgang, Kremsner, Peter, Fendel, Rolf, Addo, Marylyn M., Becker, Stephan, Sutter, Gerd, Volz, Asisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754005/
https://www.ncbi.nlm.nih.gov/pubmed/36301637
http://dx.doi.org/10.1172/JCI159895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754005/
https://www.ncbi.nlm.nih.gov/pubmed/36301637
http://dx.doi.org/10.1172/JCI159895

Ejemplares similares